EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) III - A comparison of Irish and European results

Irish Medical Journal

Volumn 102, Issue 4, 2009, Pages

  Cooney, M T ^a   Storey, S ^a   Taylor, L ^a   Dudina, A ^a   Hall, M ^b   Hemeryck, L ^b   Feely, J ^b   Graham, Ian ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE CONTROL; DRUG UTILIZATION; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; GLYCEMIC CONTROL; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT SATISFACTION; RISK REDUCTION; SECONDARY PREVENTION; SMOKING HABIT; BLOOD; COMPARATIVE STUDY; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL; EUROPE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRELAND; MALE; OBESITY; RISK FACTORS; SECONDARY PREVENTION;

EID: 67651159170     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. European Heart Network. European Cardiovascular Disease Statistics. Brussels, Belgium: European Heart Network, 2008.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modfiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
3. European Society of Cardiology and European Heart Network. European Heart Health Charter. 2007.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1-113.
5. Kotseva K, Wood D, Backer GD, Bacquer DD, Pyorala K, Keil U on behalf of the EUROASPIRE Study Group. EUROASPIRE III: a survery on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European Countries. Eur J Cardiovasc Prev Rehabil 2009 March 12 [Epub ahead of print].
6. Feely J, Graham I, Hall M, McGettigan M, O'Callaghan P, Shelley E. Comparison of Secondary Prevention of Heart Disease in Europe: Lifestyle getting worse, therapy getting better in Ireland. Irish Med J 2002;95.
7. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Heart Survey Programme. Eur Heart J 2001;22:554-572.
8. Rose G. The Strategy of Preventive Medicine: Oxford Medical Publications, 1991.
9. Unal B, Critchley J, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004;109:1101-7.